Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Alamos Gold -- Ignore unavailable to you. Want to Upgrade?

To: teevee who wrote (363)	11/10/2001 4:29:58 AM
From: Al Collard	Respond to of 4470

Hi teevee, Your in with ISA-t @$4.69 for 4,264 shares. Chart for Iso Technika, Inc: stockcharts.com[l,a]djcanimy[dc][pc20!b50!b100!b200!f][vc60][iUb14!Ll14!La12,26,9!Lp14,3,3!Lc20] From the chart of ISA we can see the stock is trading just above the support of it's 50MA on declining volume as of late. The chart indicators are all bearish but the doji candle formed from Friday's trading often signifies a turning point. So hopefully... Good luck with this pick, Al

To: teevee who wrote (363)	11/16/2001 2:28:17 PM
From: Al Collard	Read Replies (2) \| Respond to of 4470

ISA-t...in the news: Isotechnika Receives New Zealand Patent For ISA(TX)247 EDMONTON, Nov. 16 /CNW/ - Dr. Robert Foster, Chairman and CEO, of Isotechnika Inc. is pleased to announce that the Company has received the Official Issue Notification from the New Zealand Patent and Trademark Office regarding the Company's novel immunosuppressant compound, ISA(TX)247. This application has been issued New Zealand Patent No. 502362, titled, "Deuterated Cyclosporine Analogs and their uses as immunomodulating agents." "We are very pleased with the issuance of this Patent", states Dr. Randall Yatscoff, President and COO. "We look forward to this patent issuing throughout the world in the other countries in which we have filed." "The issuance of this patent is an important milestone for the Company. It provides confidence to the market regarding the intellectual property protection regarding our technology. It further strengthens our position for any future licensing negotiations", states Joseph Koziak, Executive Vice President. Isotechnika is a life sciences company headquartered in Edmonton, Alberta developing novel drugs and diagnostic products. Its lead compound, ISA(TX)247 is a novel immunosuppressive drug that can be used for prevention of organ rejection after transplantation and for treatment of autoimmune diseases such as rheumatoid arthritis and psoriasis. This drug is now in Phase 2 clinical trials in Canada and the United States. Based upon the studies completed to date, ISA(TX)247 demonstrates superior efficacy and reduced toxicity when compared with presently used medications for organ transplantation such as Cyclosporine. Current annual worldwide sales of Cyclosporine are in excess of $1.4 billion USD.